Currently, the most common regimens of adjuvant therapy are based on a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in patients with BRAF V600 mutation, as well as nivolumab or pembrolizumab (targeting programmed death receptor 1) in melanoma patients with or without BRAF V600 mutation [14,15,16,17,18,19]. This evidence concerns the gene MAP2K7 and melanoma.